X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15489) 15489
Publication (1183) 1183
Book Chapter (81) 81
Book Review (44) 44
Conference Proceeding (40) 40
Dissertation (28) 28
Magazine Article (23) 23
Book / eBook (9) 9
Newspaper Article (5) 5
Data Set (4) 4
Web Resource (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6721) 6721
index medicus (4765) 4765
pyrazines - pharmacology (4534) 4534
animals (4072) 4072
male (3933) 3933
bortezomib (3907) 3907
pyrazines - therapeutic use (3000) 3000
female (2915) 2915
middle aged (2034) 2034
pyrazines - administration & dosage (2000) 2000
pyrazine (1819) 1819
oncology (1765) 1765
pyrazines (1746) 1746
aged (1562) 1562
adult (1539) 1539
boronic acids - therapeutic use (1530) 1530
rats (1520) 1520
boronic acids - pharmacology (1480) 1480
multiple myeloma - drug therapy (1475) 1475
mice (1447) 1447
pyrazines - chemistry (1355) 1355
boronic acids - administration & dosage (1239) 1239
pharmacology & pharmacy (1184) 1184
pyrazine derivatives (1177) 1177
hematology (1162) 1162
cell line, tumor (1071) 1071
pyrazines - adverse effects (1071) 1071
antineoplastic agents - therapeutic use (1000) 1000
antineoplastic agents - pharmacology (995) 995
treatment outcome (994) 994
apoptosis (973) 973
multiple myeloma (924) 924
chemistry, organic (915) 915
apoptosis - drug effects (905) 905
cancer (888) 888
antineoplastic combined chemotherapy protocols - therapeutic use (880) 880
analysis (843) 843
dose-response relationship, drug (829) 829
biochemistry & molecular biology (812) 812
chemistry, multidisciplinary (807) 807
sitagliptin phosphate (778) 778
proteasome inhibitors (712) 712
chemistry (708) 708
pyrazines - chemical synthesis (707) 707
chemistry, medicinal (697) 697
research (687) 687
chemistry, inorganic & nuclear (684) 684
boronic acids - adverse effects (676) 676
derivatives (610) 610
molecular structure (560) 560
therapy (557) 557
structure-activity relationship (555) 555
rats, sprague-dawley (553) 553
diabetes mellitus, type 2 - drug therapy (540) 540
expression (539) 539
multiple-myeloma (537) 537
time factors (523) 523
chemistry, physical (516) 516
care and treatment (513) 513
article (509) 509
ligands (504) 504
drug therapy, combination (468) 468
pyrazines - metabolism (468) 468
protease inhibitors - pharmacology (465) 465
activation (461) 461
triazoles - therapeutic use (458) 458
cell proliferation - drug effects (456) 456
chemotherapy (456) 456
multiple myeloma - pathology (454) 454
aged, 80 and over (453) 453
protease inhibitors - therapeutic use (447) 447
dexamethasone - administration & dosage (443) 443
endocrinology & metabolism (433) 433
drug synergism (421) 421
nf-kappa-b (411) 411
in vitro techniques (407) 407
thalidomide - analogs & derivatives (407) 407
pyrazines - pharmacokinetics (403) 403
antineoplastic agents - adverse effects (400) 400
cells (397) 397
clinical trials as topic (391) 391
complexes (390) 390
food science & technology (387) 387
dexamethasone (374) 374
proteins (368) 368
hypoglycemic agents - therapeutic use (367) 367
drug therapy (365) 365
cell biology (359) 359
proteasome endopeptidase complex - metabolism (359) 359
antineoplastic agents - administration & dosage (352) 352
thalidomide - administration & dosage (348) 348
pyridine (347) 347
kinetics (338) 338
models, molecular (336) 336
abridged index medicus (332) 332
cells, cultured (331) 331
disease models, animal (328) 328
medicine & public health (328) 328
sitagliptin (328) 328
spectroscopy (325) 325
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14241) 14241
Chinese (505) 505
Japanese (174) 174
German (165) 165
French (156) 156
Italian (147) 147
Russian (60) 60
Polish (48) 48
Spanish (47) 47
Czech (27) 27
Hungarian (15) 15
Dutch (10) 10
Portuguese (10) 10
Danish (7) 7
Swedish (7) 7
Slovak (5) 5
Korean (4) 4
Norwegian (4) 4
Hebrew (3) 3
Finnish (2) 2
Romanian (2) 2
Turkish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2002, The chemistry of heterocyclic compounds, ISBN 0471403822, Volume 58
Web Resource
Blood, ISSN 0006-4971, 08/2012, Volume 120, Issue 8, pp. 1589 - 1596
The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine,... 
TRIAL | PLUS DEXAMETHASONE | ABNORMALITIES | HIGH-DOSE THERAPY | COMPLETE RESPONSE | DOXORUBICIN | PERIPHERAL NEUROPATHY | CONTINUED STANDARD CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | DELETION | Boronic Acids - toxicity | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Dexamethasone - toxicity | Induction Chemotherapy | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Antineoplastic Agents - toxicity | Multiple Myeloma - therapy | Pyrazines - toxicity | Antineoplastic Agents - adverse effects | Female | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Thalidomide - administration & dosage | Thalidomide - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Disease-Free Survival | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Stem Cells - drug effects | Stem Cells - pathology | Aged | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2015, Volume 93, pp. 330 - 337
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 26, pp. 2522 - 2533
Journal Article
Chemistry of Heterocyclic Compounds, ISSN 0009-3122, 11/2018, Volume 54, Issue 11, pp. 1075 - 1078
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 17, pp. 7773 - 7782
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article